Compare Sterling Biotech with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs TTK HEALTHCARE - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH TTK HEALTHCARE STERLING BIOTECH/
TTK HEALTHCARE
 
P/E (TTM) x -0.4 18.8 - View Chart
P/BV x 0.0 1.5 0.9% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 STERLING BIOTECH   TTK HEALTHCARE
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
TTK HEALTHCARE
Mar-19
STERLING BIOTECH/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs111,215 0.9%   
Low Rs3610 0.6%   
Sales per share (Unadj.) Rs26.8444.4 6.0%  
Earnings per share (Unadj.) Rs-15.017.2 -86.7%  
Cash flow per share (Unadj.) Rs-5.527.6 -19.8%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs54.9177.9 30.8%  
Shares outstanding (eoy) m267.8714.13 1,895.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.1 12.6%   
Avg P/E ratio x-0.552.9 -0.9%  
P/CF ratio (eoy) x-1.333.0 -3.9%  
Price / Book Value ratio x0.15.1 2.5%  
Dividend payout %029.0 0.0%   
Avg Mkt Cap Rs m1,86212,894 14.4%   
No. of employees `0001.42.3 58.6%   
Total wages/salary Rs m5471,307 41.8%   
Avg. sales/employee Rs Th5,303.32,715.7 195.3%   
Avg. wages/employee Rs Th403.8565.3 71.4%   
Avg. net profit/employee Rs Th-2,959.0105.4 -2,807.2%   
INCOME DATA
Net Sales Rs m7,1816,279 114.4%  
Other income Rs m4378 55.0%   
Total revenues Rs m7,2236,356 113.6%   
Gross profit Rs m947496 191.1%  
Depreciation Rs m2,543147 1,733.6%   
Interest Rs m4,37734 12,950.0%   
Profit before tax Rs m-5,931393 -1,510.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,924149 -1,292.3%   
Profit after tax Rs m-4,007244 -1,644.0%  
Gross profit margin %13.27.9 167.1%  
Effective tax rate %32.437.9 85.5%   
Net profit margin %-55.83.9 -1,437.5%  
BALANCE SHEET DATA
Current assets Rs m14,3352,717 527.6%   
Current liabilities Rs m49,8091,571 3,170.9%   
Net working cap to sales %-494.018.3 -2,705.7%  
Current ratio x0.31.7 16.6%  
Inventory Days Days40332 1,254.5%  
Debtors Days Days17147 365.8%  
Net fixed assets Rs m55,432991 5,593.6%   
Share capital Rs m268141 189.6%   
"Free" reserves Rs m13,9352,373 587.2%   
Net worth Rs m14,7012,514 584.7%   
Long term debt Rs m9,4783 278,760.3%   
Total assets Rs m73,9884,158 1,779.4%  
Interest coverage x-0.412.6 -2.8%   
Debt to equity ratio x0.60 47,675.4%  
Sales to assets ratio x0.11.5 6.4%   
Return on assets %0.56.7 7.5%  
Return on equity %-27.39.7 -281.2%  
Return on capital %-6.416.9 -37.9%  
Exports to sales %25.93.6 722.1%   
Imports to sales %0.20.5 34.5%   
Exports (fob) Rs m1,860225 825.8%   
Imports (cif) Rs m1231 39.4%   
Fx inflow Rs m1,860225 825.8%   
Fx outflow Rs m2571 35.0%   
Net fx Rs m1,835154 1,190.8%   
CASH FLOW
From Operations Rs m1,719173 992.9%  
From Investments Rs m-3,14897 -3,262.4%  
From Financial Activity Rs m1,426-307 -464.0%  
Net Cashflow Rs m-3-38 9.0%  

Share Holding

Indian Promoters % 33.9 65.4 51.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 3.7 -  
FIIs % 9.9 5.2 190.4%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 25.8 152.3%  
Shareholders   21,482 12,723 168.8%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Jumps 1,921 Points, FM's Tax Relief, and Top Cues in Focus Today(Pre-Open)

Share markets in India jumped sharply on Friday after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 60.1% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, TTK HEALTHCARE has posted a net profit of Rs 49 m (down 60.1% YoY). Sales on the other hand came in at Rs 1 bn (up 2.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - ORCHID PHARMA LTD COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS